Chronic graft-versus-host disease
Information
- Disease name
- Chronic graft-versus-host disease
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT01366092 | Active, not recruiting | Phase 2 | Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease | July 2011 | December 2024 |
NCT02759731 | Active, not recruiting | Phase 1/Phase 2 | Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | November 1, 2016 | May 30, 2024 |
NCT02966301 | Completed | Phase 2 | Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide | December 2016 | June 2020 |
NCT01161628 | Completed | Phase 2 | Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) | April 2011 | July 2015 |
NCT01862965 | Completed | Phase 2 | Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus | March 6, 2013 | March 2019 |
NCT01956903 | Completed | Phase 1/Phase 2 | Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. | January 2010 | September 2013 |
NCT02040623 | Completed | Phase 2 | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) | March 2014 | July 2016 |
NCT02411474 | Completed | Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD | March 2014 | August 2014 | |
NCT02991846 | Completed | A Prospective Observational Study for Evaluating CGVHD | September 1, 2017 | November 22, 2022 | |
NCT06458127 | Not yet recruiting | N/A | Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease | July 1, 2024 | March 31, 2026 |
NCT02918188 | Recruiting | Phase 2 | Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD | January 2016 | January 2031 |
NCT02611180 | Recruiting | Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease | April 30, 2015 | April 30, 2025 | |
NCT05690971 | Recruiting | N/A | Psychosocial Mobile App for Chronic Graft-Versus-Host Disease | January 23, 2023 | April 1, 2025 |
NCT02669251 | Recruiting | Phase 1/Phase 2 | Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation | April 28, 2016 | December 1, 2024 |
NCT01903473 | Terminated | Phase 2 | Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) | July 2013 | September 12, 2022 |
NCT03584516 | Terminated | Phase 2/Phase 3 | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | January 17, 2019 | November 3, 2023 |
NCT01226420 | Terminated | Phase 2 | Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease | October 2010 | August 2012 |
NCT01898377 | Terminated | Phase 2 | Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children | August 2013 | February 14, 2018 |
NCT02291770 | Unknown status | Phase 3 | Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells | October 2014 | December 2019 |
NCT01158105 | Unknown status | Phase 2 | Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) | June 2010 | January 2017 |
NCT01765660 | Unknown status | Phase 2 | Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease | January 2013 | December 2016 |
NCT04692376 | Unknown status | Phase 2 | MSC for Treatment of cGVHD After Allo-HSCT | January 10, 2021 | June 30, 2023 |
NCT01028313 | Withdrawn | Phase 2 | A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease |